Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11620477 | 0.81 | TRPA1 (0.39) | MAPT | |
| SCHEMBL8184427 | 0.77 | DPP4 (0.47) | CD274KDM4E | |
| SCHEMBL5405687 | 0.77 | PDCD1 (0.38) | CD274 | |
| Hydrochloric Acid SCHEMBL5856380 | 0.76 | DPP4 (0.46) | CD274KDM4E | |
| SCHEMBL5857430 | 0.75 | KCNA5 (0.52) | KDM4E | |
| SCHEMBL29505758 | 0.75 | TAAR1 (0.41) | HTR2ACYP3A4 | |
| SCHEMBL31070194 | 0.74 | L3MBTL1 (0.45) | SLC6A4SLC6A2ALDH1A1POLBCYP3A4 | |
| SCHEMBL22910530 | 0.72 | LTA4H (0.47) | LTA4HALDH1A1PKMPOLBKDM4E | |
| SCHEMBL6421776 | 0.71 | ALOX5AP (0.41) | — | |
| SCHEMBL11624680 | 0.71 | IDO1 (0.53) | ALDH1A1PKMMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119395-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119395-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | LTA4H 3035/4885SLC6A4 1952/4885HTR2A 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.